Halal for health: Scaling up halal pharmaceuticals
Halal standards govern lifestyle choices for 1.9bn Muslims around the world. But spending on halal products accounted for just 7% of global consumer spending on pharmaceuticals in 2018, compared with 17% of global spending on food. Moreover, predictions of growth have disappointed. The sector was expected to expand from US$92bn in 2018 to US$132bn in 2022, but that has now been pushed back to 2024.
17531
Related content
Islamic fintech: Reaching the next generation of Muslims
Muslims make up about a quarter of the world’s population and are said to be the fastest growing religious cohort.#_ftn1" name="_ftnref1" title="">[1] As such, the potential market for Islamic financial services is enormous. The median age for Muslims globally is just 24 years old, making a majority of them “digital natives” ready for digital Islamic financial solutions.
“You're not going to be able to access that younger generation if you’re not in the palm of their hand,” says Aris Parviz who heads the North American operations for Wahed Invest, a sharia-compliant - or halal - digital investment platform.
Islamic fintech marries sharia compliance with digitally-delivered financial solutions. This makes it easier for Muslims to access savings, investments, insurance and mortgages that are in line with the principles of their faith. Particularly during the coronavirus pandemic, as countries implement social distancing measures, financial companies are relying on digital channels to ensure customers have access to their services.
Key characteristics of sharia-compliant or halal investing
✖ Profiting from debt is prohibited
✖ Interest payments are prohibited
✖ Investing in businesses that profit from alcohol, arms, tobacco and gambling is forbidden
✔ Earnings are generated through profit-sharing
✔ Islamic finance instruments must be backed by real assets
For Wahed Invest’s co-founder, Junaid Wahedna, the need for such services became clear after his encounter with a New York taxi driver. The Muslim driver was looking for ways to invest in accordance with the values of his faith and sought advice from his imam. His imam’s advice was to put his life savings into Apple stocks. The company’s relatively low debt levels, the imam surmised, made it permissible. “Now, Apple is an amazing company today, but it could have been the AOL of the 1990s,” says Mr Parviz. “No one thought AOL was going to go under, and then what happened?”
The conversation drove Mr Wahedna to establish a sharia-compliant robo-advisory investment firm. “The average person doesn't know too much about Islamic finance investing and doesn’t have access to financial advisors,” Mr Parviz explains. “Our aim is to give Muslims across the globe access to financial markets, to help them improve their financial wellbeing.”
Since launching in 2017, Wahed Invest has amassed over 50,000 users and established offices in the US, UK and Malaysia. “The whole Islamic faith is over 1.8bn people,” says Mr Parviz. “It’s an amazing opportunity because a lot of the conventional players don’t pay attention to it.”
Yielders, a UK-based property investment crowdfunding platform, was born of similar frustrations. “Growing up as a Muslim in the UK, there was a real lack of investment opportunities that did not compromise my faith,” says Irfan Khan, its founder. “Most of the available opportunities were either interest-bearing or too high risk.” His platform lets investors buy into buildings already earning a rental income with as little as £100, without interest or leverage.
Delivering Islamic fintech
Businesses offering Islamic investment solutions digitally must deliver on two fronts: compliance and access.
To ensure compliance with sharia law, fintechs have to navigate an intricate set of rules. Interest charges, or riba, are prohibited. So too are investments in “sin stocks” of businesses profiting from alcohol, arms, tobacco and gambling. The rules also prohibit profiting from debt and require investments to be backed by real assets. This has led to the creation of sukuk—sharia-compliant financial certificates, similar to bonds, which give an investor part-ownership of an underlying asset. There are also detailed investment criteria surrounding a company’s leverage and interest income.#_ftn2" name="_ftnref2" title="">[2]
For access, selecting the right technologies is key. Fintechs are deploying a growing array of halal payment platforms, e-wallets, insurtech and remittance services through mobile phone apps. New digital Islamic banks such as the UK’s Niyah and Germany’s Insha are offering interest-free products through similar channels.
Beyond product delivery, technologies used by fintech firms promise to bolster Islamic finance by driving efficiencies and reducing costs. In turn this could cut costs of payment services and transactions, says Mohamed Damak, global head of Islamic finance at ratings agency S&P Global Ratings.
Technologies such as artificial intelligence might also help to improve compliance. Blockchain, if deployed at scale, has the potential to reduce the risk of fraudulent transactions, Mr Damak argues. Emirates Islamic Bank is already using the technology to authenticate paper cheques in the United Arab Emirates.#_ftn3" name="_ftnref3" title="">[3]
Blockchain for sukuk
To address high costs and a lack of transparency within the sukuk market, “blockchain could literally be the missing link,” according to Mr Damak of S&P Global Ratings.
He expects blockchain technologies will open the market to smaller companies by cutting the cost of issuing a sukuk. In 2019 an Indonesian microfinance institution, BMT Bina Ummah, used a platform created by startup company Blossom Finance to raise US$50,000 in what it claimed to be the first blockchain sukuk.
On transparency, he explains: “At present an issuer can substitute one underlying asset with another without informing investors, even though it can completely change the risk profile of the transaction. Blockchain will resolve that by documenting every change.”
In addition, in instances where there are dozens of assets underlying a single certificate, he predicts that the technology will show investors in real time which ones are underperforming.
The Islamic fintech environment
To achieve ambitious expansion plans, young Islamic fintech firms require a supportive business environment. Incubators are springing up in the Middle East#_ftn4" name="_ftnref4" title="">[4] and Malaysia is home to more than 200 fintech startups given its strong public support of the digital economy.#_ftn5" name="_ftnref5" title="">[5]
Harmonising regulation between countries is an important step. When US-headquartered Wahed Invest first entered Malaysia “the whole concept of sharia-compliant robo-advisory was very new,” Mr Parviz recalls. “So, the regulators had to issue us with a new type of licence altogether.”
Investment, however, is only trickling into sharia-compliant fintech. “There are still very few venture capital and private equity firms that are actively looking at investing in this space because it’s new and they’re waiting to see who’s going to develop the market,” says Mr Khan of Yielders.
“Islamic finance is a US$2trn industry, so for fintech to have a meaningful impact on its growth we need lots of investment, and that is not something we’re really seeing,” Mr Damak echoes.#_ftn6" name="_ftnref6" title="">[6] Among the handful of players are US-based private equity group Frost Capital (which invested US$8m in Affinis Labs, a company that builds Islamic business innovation ecosystems) and Wahed Invest’s investors Boston-based Cue Ball Capital and BECO Capital, a Middle Eastern venture capital firm.
Widening the consumer base
In places where Islamic fintech vies with conventional alternatives, startups will have to compete on more than their religious credentials. “Sharia compliance will help them attract a certain percentage of their market,” Mr Damak explains. “But the biggest portion will be people who would have a preference for Islamic products but go for conventional alternatives if they are cheaper [or offer higher returns].”
When it comes to portfolio investment, “[sharia-compliant models] perform quite competitively as compared to the broader market,” argues Wahed Invest’s Mr Parviz.#_ftn7" name="_ftnref7" title="">[7], #_ftn8" name="_ftnref8" title="">[8] This allows Islamic fintechs to “actually attract some folks who are just interested in the ethical aspects of it,” he says.
In the UK, the competitive savings rates offered by brick-and-mortar Islamic banks have attracted a host of non-religious depositors.#_ftn9" name="_ftnref9" title="">[9] Yet in general they lack their competitors’ economies of scale. High prices for products such as mortgages drive many consumers towards conventional alternatives. If advanced technologies can help to reduce costs, Islamic fintechs might win them over.
More importantly, Mr Khan warns that “many of the newer fintechs need to be careful about how they’re pitching themselves—not to make the same mistakes as traditional financial institutions by focusing [only] on that core Islamic market.”
His solution is to pitch to a wider market. Yielders does not actively promote its Islamic credentials. Almost a quarter of its investors are non-Muslims, a share which Mr Khan wants to grow to more than two-thirds. “I didn’t want people to come to us just because we were sharia-based,” he says. “I wanted people to come to the platform firstly because of the returns that we offered.”
Deploying sharia-compliant financial solutions through digital channels could drive the next wave of growth for Islamic finance. Islamic fintech is poised to deliver financial services sought by a young, middle-class Muslim community that has largely been ignored as well as those seeking ethical financial solutions at the speed and cost of modern finance.
#_ftnref1" name="_ftn1" title="">[1] Michael Lipka, “ Muslims and Islam: Key findings in the U.S. and around the world”, Pew Research: Fact Tank, August 9th 2007. https://www.pewresearch.org/fact-tank/2017/08/09/muslims-and-islam-key-f... #_ftnref2" name="_ftn2" title="">[2] A M A Ayedh, A Shaharuddin, M I H Kamaruddin, “ Shariah Screening Methodology: Does It 'Really' Shariah Compliance?”, IQTISHADIA, 2019. https://www.researchgate.net/publication/337904142_Shariah_Screening_Met...'Really'_Shariah_Compliance #_ftnref3" name="_ftn3" title="">[3] “Emirates Islamic is first Islamic bank to integrate blockchain technology into cheques”, Emirates Islamic, June 11th 2017. https://www.emiratesislamic.ae/eng/latest-news/2017/june/news11062017/ #_ftnref4" name="_ftn4" title="">[4] “The race to become Islamic banking’s fintech hub”, The Economist, June 1st 2017. https://www.economist.com/finance-and-economics/2017/06/01/the-race-to-b... #_ftnref5" name="_ftn5" title="">[5] “Malaysia: A Flourishing Fintech Ecosystem”, International Monetary Fund, February 28th 2020. https://www.imf.org/en/News/Articles/2020/02/27/na022820-malaysia-a-flou... #_ftnref6" name="_ftn6" title="">[6] https://www.spglobal.com/ratings/en/research/articles/190624-islamic-fin... #_ftnref7" name="_ftn7" title="">[7] L Trabelsi, F Mathlouthi, S Bahloul, “Performance analysis of Islamic and conventional portfolios: The emerging markets case”, Borsa Istanbul Review, Vol. 20, No. 1, pages 48-54, 2020. https://www.sciencedirect.com/science/article/pii/S2214845019302790 #_ftnref8" name="_ftn8" title="">[8] M González, F Jareño, C Haddouti, “Sector Portfolio Performance Comparison between Islamic and Conventional Stock Markets”, Sustainability, Vol. 11, No.17, 2019. https://www.mdpi.com/2071-1050/11/17/4618 #_ftnref9" name="_ftn9" title="">[9] “Why non-Muslims are converting to sharia finance”, The Economist, October 20th 2018. https://www.economist.com/britain/2018/10/20/why-non-muslims-are-convert...Islamic finance: The race is on
When Goldman Sachs gets involved, things all of a sudden seem much more serious. Such is the case with news the US bank has revived plans to issue its first sukuk (the Islamic equivalent of a bond), reflecting what Reuters called “a sign that Islamic finance is going mainstream.”
Probably the more tell-tale sign was in June when the UK issued its first sovereign sukuk, which was 10 times oversubscribed. Either way, it’s illustrative of the fact that Islamic finance is one of the few areas of the financial services industry—perhaps the only one—growing at a double-digit pace. Total assets in the sector are expected to reach US$2trn this year, a pool large enough for prominent sovereign issuers and banks in the West to take notice.
The rising popularity of Islamic finance in the West is unsurprising to Malaysia’s central bank governor, Zeti Akhtar Aziz. In an interview at Sasana Kijang, the central bank’s sparklingly modern meeting hall in Kuala Lumpur, Ms Zeti noted that unlike most forms of traditional credit creation, Islamic finance has to be backed by real assets and this is one of its most unique and attractive aspects, whether a borrower is in the West or not.
Furthermore, she believes Islamic finance can support the trend seen since the financial crisis of growing trade and investment ties between emerging markets around the world.
“Trade patterns are changing, and there is a greater volume of trade happening between developing economies. This needs to be supported by finance, and Islamic finance because it’s linked to economic transactions… will facilitate this kind of economic activity,” Ms Zeti said.
“This is not just for Muslims. It’s a form of financial intermediation.”
Indeed, global banks are keen to get a piece of the pie. To do that, they need size and expertise when it comes to structuring deals that adhere to shariah law. This is no small feat, as Goldman Sachs can attest after the bank encountered criticism that an initial attempt in 2011 to launch sukuk securities did not follow shariah requirements.
Malaysia’s central bank has been supportive of creating a home-grown mega Islamic bank with at least US$1bn in assets to boost the domestic industry’s cross-border transaction capabilities. “You really need size to be able to do international deals,” Ms Zeti said.
CIMB, Malaysia's second-largest lender, in July said it plans to create a mega Islamic bank by merging with RHB Capital and Malaysia Building Society. If the deal takes place—terms won’t be finalised until October—the combined entity will potentially be able to compete with conventional banks on a global stage in the fast-growing international Islamic finance industry.
The prospect of Malaysia contributing a global player in Islamic finance is certainly welcome and would add to the breath-taking pace at which companies, industries and entire markets in Asia have been internationalising in the past several years.
Is Malaysia’s banking industry ready to broker deals for a much larger population of foreign sukuk issuers? “The perceptions of our local investors are that sometimes is not easy to find a good foreign [sukuk] issue in local currency because they might not be familiar with the company,” Mohd Daud Bakar, founder and chairman of Amanie Advisors, a shariah advisory firm, said at a panel discussion organised by The Economist Events. “Big investment houses like to deal with people they know.”
Local banks may have their work cut out for them.
For a complete playback of the panel discussion on local currency debt, click here.
The views and opinions expressed in this article are those of the authors and do not necessarily reflect the views of The Economist Intelligence Unit Limited (EIU) or any other member of The Economist Group. The Economist Group (including the EIU) cannot accept any responsibility or liability for reliance by any person on this article or any of the information, opinions or conclusions set out in the article.
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Making the most of opportunity: Pharmaceutical strategy in Asia
The growth potential of Asia’s pharmaceutical markets is astounding. Indeed, pharmaceutical spending in the region is projected to rise faster than GDP. However, pharmaceutical companies face a variety of strategic challenges. Making the most of opportunity: Pharmaceutical strategy in Asia, an Economist Intelligence Unit (EIU) report sponsored by the Singapore Economic Development Board, explores how pharmaceutical companies operating in Asia can best navigate opportunities for continued expansion.
Related content
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.
Le système de santé fondé sur la valeur en France
Related content
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.
Value-based healthcare in France
Related content
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.
Value-based healthcare in France: A slow adoption of cost-effectiveness criteria
Key findings
- In France, the level of improvement is a key determinant rather than price in deciding how innovation is valued.
- Patient access to new drugs is highly valued and influential in how the French healthcare system is organised.
- A lack of transparency in the way in which final prices for new drugs are negotiated curbs progress of value-based healthcare in France.
More from this series
Related content
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.
Pharma’s value proposition
The Pharma Summit 2011 brings together top pharma players to present an outlook of the pharma industry in the long term. In this video David Redfern, Chief Strategy Officer at GlaxoSmithKline, discusses how the industry must change.
Related content
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.
On rebranding pharma
This video is one of the selected highlights from some of the experts on the subject of health and wellbeing, as part of The Big Ideas Project. Jonathan Sands, Chairman of Elmwood shared his thoughts on "rebranding pharma".
Related content
The shifting landscape of global wealth: Future-proofing prosperity in a ti...
In some instances the impact of this shift will be shaped by local factors, such as demographic changes. In other instances this shift will reflect shared characteristics, as demonstrated by the greater popularity of overseas investing among younger high-net-worth individuals (HNWIs) brought up in an era of globalisation. Whatever the drivers, the landscape of wealth is changing—from local to global, and from one focused on returns to one founded on personal values.
Despite rising economic concerns and a tradition of investor home bias in large parts of the world, the new landscape of wealth appears less interested in borders. According to a survey commissioned by RBC Wealth Management and conducted by The Economist Intelligence Unit (EIU), younger HNWIs are substantially more enthusiastic about foreign investing. The U.S. is a particularly high-profile example of a country where a long-standing preference for investments in local markets appears set to be transformed.
Click the thumbnail below to download the global executive summary.
Read additional articles from The EIU with detail on the shifting landscape of global wealth in Asia, Canada, the U.S. and UK on RBC's website.
Fintech in ASEAN
To better understand the opportunities and challenges in developing a fintech business in seven ASEAN markets, The Economist Intelligence Unit conducted wide-ranging desk research supplemented by seven in-depth interviews with executives in Australia and ASEAN.
Download report and watch video interview to learn more.
Risks and opportunities in a changing world
Read our Taxing digital services, U.S. tax reform: The global dimension, & Planning for life after NAFTA articles by clicking the thumbnails below.
On the future for research led-pharma
In this video, John Lechleite, President and Chief Executive Officer at Eli Lilly, opens The Pharma Summit 2011 by sharing his views on the future of the industry, and poses the question: can big pharma can continue to be research-led?
Related content
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.
The value challenge
Report Summary
The value challenge is the second in a series of four reports by the Economist Intelligence Unit, following the first report, The innovation imperative in biopharma. These reports are part of the Reinventing biopharma: Strategies for an evolving marketplace programme, sponsored by Quintiles. The Economist Intelligence Unit conducted the survey and analysis and wrote the report. The findings and views expressed in this report do not necessarily reflect the views of the sponsor.
More from this series
white paper
The value challenge
Research methodology The value challenge is the second in a series of four reports by the Economist Intelligence Unit
case study
In search of value: Shire Pharmaceuticals changes its business model
A decade ago Shire Pharmaceuticals' business model centred on the improvement and reformulation of existing drugs. The
case study
Value and oncology: a different definition?
Oncology is the therapeutic area in which the value challenge is most acute. According to 41% of survey respondents and
Related content
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.